Ren Liangliang, Li Ling, Zhang Lei, Li Xin, Fu Xiaorui, Wang Xinhua, Wu Jingjing, Sun Zhenchang, Feng Xiaoyan, Chang Yu, Zhou Zhiyuan, Nan Feifei, Yan Jiaqin, Kong Fei, Zhang Mingzhi
Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 Henan People's Republic of China.
Indian J Hematol Blood Transfus. 2022 Jan;38(1):42-50. doi: 10.1007/s12288-021-01433-w. Epub 2021 Apr 12.
Limited treatment options are available for relapsed or refractory diffuse large B cell lymphoma (RR DLBCL). Few clinical studies have reported the use of Ibrutinib, a covalent Bruton Tyrosine kinase (BTK) inhibitor, in RR DLBCL. There are relatively few clinical studies about Ibrutinib in RR DLBCL now. We retrospectively investigated the safety and efficacy of Ibrutinib (alone or in combination with other drugs) in patients with RR DLBCL. We reviewed the medical records of 40 RR DLBCL patients who received Ibrutinib alone or in combination with other drugs in our hospital from June 2018 to August 2020. The objective response rate (ORR) of RR DLBCL patients on Ibrutinib was 22.5%. The median progression free survival time (PFS) was 13.0 months (95% CI 8.914-17.086), and the median overall survival time (OS) was 15.0 months (95% CI 11.931-18.089). Rash (25.0%) and fatigue (25.0%) were the most common adverse reactions in this study. The application of Ibrutinib to patients with RR DLBCL has good short-term efficacy, and the adverse reactions are well tolerated. Combined treatment of Ibrutinib with other drugs has been found to more effective than Ibrutinib therapy alone.
复发或难治性弥漫性大B细胞淋巴瘤（RR DLBCL）的治疗选择有限。很少有临床研究报道使用共价布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼治疗RR DLBCL。目前关于依鲁替尼治疗RR DLBCL的临床研究相对较少。我们回顾性研究了依鲁替尼（单独或联合其他药物）治疗RR DLBCL患者的安全性和疗效。我们查阅了2018年6月至2020年8月期间在我院接受依鲁替尼单药治疗或联合其他药物治疗的40例RR DLBCL患者的病历。接受依鲁替尼治疗的RR DLBCL患者的客观缓解率（ORR）为22.5%。中位无进展生存期（PFS）为13.0个月（95%CI 8.914-17.086），中位总生存期（OS）为15.0个月（95%CI 11.931-18.089）。皮疹（25.0%）和疲劳（25.0%）是本研究中最常见的不良反应。依鲁替尼应用于RR DLBCL患者具有良好的短期疗效，且不良反应耐受性良好。已发现依鲁替尼与其他药物联合治疗比单药依鲁替尼治疗更有效。
